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SOMMARIO 
L’arteriopatia periferica aterosclerotica degli arti inferiori (PAD) è una patologia 
che colpisce circa il 20% dei soggetti al di sopra dei 70 anni. La claudicatio inter-
mittens (IC), che ne è il principale sintomo, è un dolore che si presenta tipicamen-
te ai polpacci durante il cammino. Questo sintomo limita la capacità di camminare 
dei pazienti influendo negativamente sul loro ruolo sociale, sul livello di attività 
fisica, e sulla qualità di vita. La terapia principale per l’IC è l’esercizio fisico su-
pervisionato. Tuttavia se è chiaro il ruolo che quest’ultimo svolge 
nell’incrementare la capacità di marcia dei pazienti, non è altrettanto chiara la ti-
pologia ottimale di esercizio da proporre. Il trattamento abitualmente utilizzato in-
clude esclusivamente cammino ed esercizi aerobici, vi sono tuttavia le basi per 
suppore che i pazienti potrebbero beneficiare dell’aggiunta di esercizi anaerobici 
di forza al loro protocollo di allenamento.  
Nel nostro studio si sono testati gli effetti di un protocollo di allenamento combi-
nato, rispetto al protocollo standard attualmente in uso. 24 soggetti sono stati divi-
si in 2 gruppi ed hanno preso parte a 3 mesi di allenamento. All’inizio ed al termi-
ne dello stesso sono stati misurati: la capacità di marcia libera da dolore e totale, i 
principali parametri cardiovascolari durante esercizio, la forza, l’equilibrio, la va-
riabilità del ciclo del passo e l’attività svolta quotidianamente. 
I risultati ci hanno mostrato una simile capacità dei due protocolli d’incrementare 
la massima capacità di marcia. Abbiamo inoltre evidenziato il ruolo che le modi-
fiche nella variabilità del ciclo del passo potrebbero avere in tale incremento. Il 
protocollo combinato si è dimostrato invece più efficace nell’incrementare la ca-
pacità di marcia libera da dolore. Inoltre l’allenamento combinato ha incrementato 
l’iperemia dell’arto in corso di attività fisica, così come ha migliorato importanti 
parametri di performance cardiorespiratoria (consumo di ossigeno, frequenza car-
diaca, pressione arteriosa, estrazione di ossigeno). Abbiamo anche documentato la 
capacità dell’allenamento combinato di migliorare la forza muscolare e 
l’equilibrio riducendo il rischio di cadute. Abbiamo infine osservato il trasferi-
mento degli effetti positivi nella vita quotidiana con uno stile di vita meno seden-
tario. L’allenamento combinato potrebbe quindi essere utilizzato nei pazienti con 
IC per migliorare non solo la performance ma anche la forza e l’equilibrio.  
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Possiamo quindi concludere che l’utilizzo del protocollo combinato, al posto del 
protocollo di allenamento standard, dovrebbe essere preso in considerazione nel 
trattamento dei pazienti con IC. 
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ABSTRACT 
Peripheral artery disease (PAD) is a pathology of lower limbs affecting about 20% 
of people older than 70 years. Intermittent claudication (IC) is the most frequent 
symptom of PAD. IC is pain experienced during walking, typically in the calf. 
This limits the walking ability of patients and reduces social role, physical activity 
and quality of life. The main therapy for IC is supervised exercise. Whereas the 
primary role of supervised exercise in treatment of IC is well established there are 
some doubt about the best typology of exercise. Usually training includes only 
walking and aerobics exercises, but some elements suggested that for this patients 
adding strength exercises may be useful.  
In our study we tested the effects of combined training against usually standard 
training. We divided 24 subjects in two groups and they were trained for 3 
months. At the beginning and at the end of training we measured: total and pain 
free walking distance, main cardiovascular parameters during exercise, strength, 
balance, gait variability and daily physical activity.  
According to our results the two different training protocols have similar power to 
improve total walking distance. We also underlined the role that changes in gait 
variability can play in this increment. Combined training is more effective in im-
proving pain free walking distance. Moreover combined training increased limb’s 
hyperemia during exercise, and improved important index of cardiorespiratory 
performance (oxygen consumption, heart rate, blood pressure, oxygen extraction). 
We also recorded the usefulness of combined training in improving strength and 
balance and lowering falls risk. We also observed the persistence of this effects in 
daily life, with a more active life style. 
So combined protocol should be taken into account as alternative treatment for pa-
tients with IC. 
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1. BACKGROUND 
Peripheral arterial disease of lower extremity arteries (PAD) is a pathology in-
cluded in the category of peripheral arterial disease, a range of noncoronary arteri-
al syndromes that are caused by the altered structure and function of the arteries 
that supply the brain, visceral organs, and the limbs. It leads to progressive steno-
sis or occlusion of one or more arterial branches that supply lower extremities.  
Arterial diseases include those disorders that cause either fixed obstruction or ab-
normal vascular reactivity of the arteries that supply a given tissue; the obstruction 
impairs blood delivery and can produce ischemia. 
Numerous pathophysiological processes can contribute to the creation of steno-
sis/occlusions of the noncoronary arterial circulation, but atherosclerosis remains 
the most common disease process. Risk factors for atherosclerosis such as ciga-
rette smoking, diabetes, dyslipidemia, hypertension and hyperhomocysteinemia 
increase the likelihood of developing lower extremity PAD
1,2
. 
 
1.1. Risk factors for peripheral arterial disease 
 
1.1.1. Unchangeable risk factors 
Race, gender, age, familiarity. 
 
1.1.1.1. Race 
The pathology has higher prevalence for Blacks (7,8%) than for Whites (4,4%), 
regardless of other risk factors
3
. 
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1.1.1.2. Gender 
The prevalence of PAD is slightly greater in men than women
2
, the ratio of men to 
women is between 1:1 and 2:1. 
 
1.1.1.3. Age 
The prevalence of the pathology increases with increasing age
2
. The prevalence of 
asymptomatic PAD is in the range of 3% to 10% in the general population, in-
creasing to 15% to 20% in persons over 70 years
4
. The symptomatic PAD with in-
termittent claudication (IC) has a prevalence of 3% at the age of 40, whereas  it 
reaches 6% at the age of 60. 
 
1.1.2. Changeable risk factors 
Cigarette smoking, diabetes, dyslipidemia, hypertension, hyperhomocysteinemia, 
chronic inflammation, blood hyperviscosity and hypercoagulability. 
 
1.1.2.1. Cigarette smoking  
Cigarette smoking is an exceptionally powerful etiologic risk factor for lower ex-
tremity PAD, even more than for coronary artery disease. Large epidemiological 
studies have found that smoking increases the risk of lower extremity PAD by 2- 
to 6-fold and the risk of intermittent claudication by 3- to 10-fold
1,5,6
. More than 
80% of patients with lower extremity PAD are current or former smokers
7
. The 
risk of lower extremity PAD increases in a powerful dose-dependent manner with 
the number of cigarettes smoked per day and the number of years smoked
8
. Smok-
ing cessation is associated with a decline in the incidence of IC, the relative risk 
decreases from 3,7 in smokers to 3 in ex-smokers, who had discontinued smoking 
since less than 5 years
2
. 
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1.1.2.2. Diabetes 
Diabetes mellitus increases the risk of lower extremity PAD by 2- to 4-fold, and 
the risk of IC by 3,5-fold in men and 8,6-fold in women
1
. Between 12% and 20% 
of persons with lower extremity PAD are also diabetics
9
. The risk of developing 
lower extremity PAD is proportional to the severity and duration of diabetes
10
, for 
every 1% increase in glycosylated hemoglobin there is a corresponding 26% in-
creased risk of PAD
11
. PAD in patients with diabetes is more aggressive com-
pared to non-diabetics, with early large vessel involvement coupled with distal 
symmetrical neuropathy
2
. The need for a major amputation is 7- to 15-times high-
er in diabetics than non-diabetics
12
. This is contributed to by sensory neuropathy 
and decreased resistance to infection. Very important is also the role played by in-
sulin resistance
13
, which is a risk factor for PAD even in subjects without diabe-
tes, raising the risk approximately by 40% to 50%. 
 
1.1.2.3. Dyslipidemia 
Low-density lipoprotein (LDL) and total cholesterol levels are generally higher, 
and those of high-density lipoprotein (HDL) are lower, in patients with intermit-
tent claudication than in age-matched controls. Elevated levels of triglycerides 
have been reported to be associated with lower extremity PAD in some studies but 
not in others. The risk of developing lower extremity PAD increases by approxi-
mately 5% to 10% for each 10 mg per dl rise in total cholesterol, and a fasting 
cholesterol level greater than 7 mmol/L (270 mg/dl) was associated with a dou-
bling of the incidence of IC, but the ratio of total to HDL cholesterol was the best 
predictor of occurrence of PAD
1,2
. 
 
1.1.2.4. Hypertension 
Hypertension is associated with lower extremity PAD, although the association is 
generally weaker than that with coronary artery disease. One study assessed that 
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hypertension increases the risk of IC 2,5- to 4-fold in men and women, respective-
ly, and the risk is proportional to the severity of high blood pressure
6,1
. 
 
1.1.2.5. Hyperhomocysteinemia  
Elevated levels of homocysteine (greater than 12,1 micromoles per liter) are asso-
ciated with a 2- to 3-fold increased risk for developing atherosclerotic arterial dis-
ease, with an increased risk of approximately 1,5-fold for each 5 micromoles per 
liter increment in homocysteine level
14
. Hyperhomocysteinemia also appears to 
increase the risk of progression of lower extremity PAD
1
. 
 
1.1.2.6. Chronic inflammation 
C-reactive protein is a serological marker of systemic inflammation. C-reactive 
protein concentrations in the highest quartile are associated with a 2,1-fold in-
creased risk of developing lower extremity PAD. One study noted that C-reactive 
protein levels were higher in individuals who subsequently developed lower ex-
tremity PAD and highest in those who ultimately required vascular surgery
15
. 
 
1.1.2.7. Blood hyperviscosity and hypercoagulability 
Raised hematocrit levels and hyperviscosity have been reported in patients with 
PAD, possibly as a consequence of smoking. Increased plasma levels of fibrino-
gen, which is also a risk factor for thrombosis, have been associated with PAD in 
several studies. Both hyperviscosity and hypercoagulability have also been shown 
to be markers or risk factors for a poor prognosis
2
. 
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1.1.2.8. Low levels of physical activity 
In healthy populations, higher physical activity levels are associated with lower 
all-cause and cardiovascular disease mortality
16
. Because ambulation is one of the 
primary physical activities performed by the elderly, it is not surprising that PAD 
subjects adopt a sedentary lifestyle. Indeed IC limits ambulatory ability of patients 
decreasing physical activity and affecting health related quality of life. 
The poor prognosis of patients with PAD is further compounded by sedentary liv-
ing. The mortality risk of sedentary PAD patients is higher than their more physi-
cally active counterparts
17
. Patients limited by intermittent claudication who en-
gage in any amount of weekly physical activity beyond light intensity at baseline 
have a lower mortality rate than their sedentary counterparts who perform either 
no physical activity or only light-intensity activities. The protective effect of phys-
ical activity persists even after adjusting for other predictors of mortality. 
  
1.2. Stages of pathology 
The disease has different stages of severity and tends to progress, similarly to 
what happens to other diseases of atherosclerotic origin. 
Few studies of the natural history of PAD have been performed to objectively 
quantify disease progression, claudication symptoms usually remain stable and do 
not worsen or improve at rapid rates. Thus, after 5 to 10 years, more than 70% of 
patients report either no change or improvement in their symptoms, while 20% to 
30% have progressive symptoms and require intervention, and less than 10% need 
amputation
18
.  
Stages of pathology are described in the classification of Fontaine/ Rutherford 
(Figure1). 
Pathology in the early stage is asymptomatic. 
In the advanced stage, or with more important degrees of stenosis/occlusion, ap-
pears the main symptom of PAD, intermittent claudication (IC). 
Claudication is defined as fatigue, discomfort, or pain that occurs in specific limb 
muscle groups during effort due to exercise-induced ischemia. Individuals with IC 
14 
 
have sufficient blood flow so that limb ischemic symptoms are absent at rest. 
With increased local muscular demand for metabolic support during exercise, the 
increase in blood flow limited by arterial occlusive lesions is inadequate to meet 
this demand, and limb muscular fatigue and/or pain results. 
The anatomic site of the arterial stenosis is often associated with specific leg 
symptoms. Occlusive disease in the iliac arteries may produce hip, buttock, and 
thigh pain, as well as calf pain. Occlusive disease in the femoral and popliteal 
arteries is usually associated with calf pain. Occlusive disease in the tibial arteries 
may produce calf pain or, more rarely, foot pain and numbness. 
Usually pain is relieved by rest within 10 minutes. 
Some patients have atypical claudication symptoms, and typical claudication 
symptoms may not occur in patients who have co-morbidities that prevent suffi-
cient activity to produce limb symptoms, or in patients who are so deconditioned 
that exercise is not performed. 
When occlusion involves larger segments of the arterial tree, perfusion is progres-
sively compromised, up to determine rest pain and subsequently ischemia with 
necrosis. 
                  Fontaine  
Stage                           Clinical  
I                                  Asymptomatic  
IIa                               Mild claudication  
IIb                               Moderate-severe claudication  
III                                Ischemic rest pain  
IV                                Ulceration or gangrene 
 
 
 
                 Rutherford 
 
Grade          Category          Clinical 
0                   0                     Asymptomatic 
I                    1                     Mild claudication 
I                    2                     Moderate claudication 
I                    3                     Severe claudication 
II                   4                     Ischemic rest pain 
III                  5                     Minor tissue loss 
IV                  6                     Ulceration or gangrene 
Figure 1: classification of disease severity according to Leriche-Fontaine’s Stages and Ruth-
erford’s Categories. 
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1.3. Coexisting vascular disease 
Because PAD is one of manifestations of atherosclerosis, it is not surprising that 
this disease commonly occurs together with others of same origin. 
PAD is associated with coronary artery disease in 40% - 60% of patients. 
The link with cerebral artery disease seems to be weaker, carotid artery disease 
occurs in 26% to 50% of patients with IC, but only about 5% of patients with 
PAD will have a history of any cerebrovascular event. 
Between 23% and 43% of patients with PAD have renal artery stenosis of 50% or 
over
2
. 
As a consequence of coexisting coronary and cerebral artery disease, patients with 
PAD have an increased risk of myocardial infarction, ischemic stroke and vascu-
lar death. 
There is a 20% to 60% increased risk for myocardial infarction and a 2- to 6-fold 
increased risk of death due to coronary heart disease events. The risk of stroke is 
increased by approximately 40%. 
It is very likely that renal artery stenosis is also a partly independent risk 
factor for mortality in patients with PAD since renal artery stenosis of 50% or 
over is associated with a 3,3-fold higher mortality rate than in the general popula-
tion
2
. 
The mortality rate of patients with PAD depends on the stage of the disease and is 
from 4% to 6% higher in those with more severe condition. The 1-year mortality 
rate in patients with critical limb ischemia is approximately 25% and may be as 
high as 45% in those who have undergone amputation
1
. 
 
1.4. Diagnostic methods 
The vascular physical examination includes inspection of feet, evaluation of color, 
temperature, and integrity of the skin and intertriginous areas, and search for addi-
tional findings suggestive of severe PAD, including distal hair loss, trophic skin 
changes, hypertrophic nails, and the presence of ulcerations. Then blood pressure 
16 
 
is measured, the ankle-brachial index (ABI) is calculated and hemodynamic or 
imaging analysis are effectuated.  
To make diagnosis of PAD numerous physiological noninvasive tests are availa-
ble. These are relatively inexpensive, can be performed at no risk, and provide 
prognostic information. Some of these examinations permit to localize lesions to 
specific limb arterial segments. Moreover some second level invasive analysis 
such Computed Tomographic Angiography and Magnetic Resonance Angi-
ography are available and should be effectuated in case of worsening of the dis-
ease. 
 
1.4.1. Ankle-Brachial Index (ABI) 
Measuring the pressure in the ankle arteries has become a standard part of the ini-
tial evaluation of patients with suspected PAD
19,20,21
. 
The ABI is a measurement that provides objective data that serve as the standard 
for the diagnosis of lower extremity PAD. It can be used either as a screening tool 
for lower extremity PAD or to monitor the efficacy of therapeutic interventions. 
The ABI should become a routine measurement for asymptomatic subjects be-
longing to high risk groups, including all persons over the age of 70, patients aged 
50–69 years who also had diabetes or a smoking history, and subjects younger 
than 49 years with an history of diabetes and another atherosclerotic risk factor
2
. 
The ABI is performed by measuring the systolic blood pressure from both brachi-
al arteries and from both the dorsalis pedis and posterior tibial arteries after the 
patient has been at rest in the supine position for 10 minutes. The blood pressure 
ratio is calculated using the higher of the considered ankle systolic pressures (pos-
terior tibial or dorsalis pedis) divided by the higher arm systolic pressure, left or 
right arm (in normal individuals, there should be a minimal interarm systolic pres-
sure gradient, less than 12 mm Hg). Optimal recordings are obtained with blood 
pressure cuffs that are appropriately sized to the patient’s lower calf, immediately 
above the ankle, and systolic pressures are recorded with a handheld 8- or 10-mHz 
doppler instrument
1
.   
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Pulse wave reflection in healthy individuals causes the ankle pressure to be 10 to 
15 mm Hg higher than the brachial arterial systolic pressure, and thus the normal 
ankle-arm brachial index systolic blood pressure ratio is greater than 1,00 (calcu-
lated ABI values should be recorded to 2 decimal places). 
The ABI provides considerable information. A reduced ABI in symptomatic pa-
tients confirms the existence of hemodynamically significant occlusive disease 
between the heart and the ankle, with a lower ABI indicating a greater hemody-
namic severity of occlusive disease. 
The threshold value of ABI to make diagnosis of PAD is ≤ 0,90 at rest. 
Abnormal ABI values represent a continuous variable less than 0,90. ABI values 
are often considered to be mildly to moderately diminished when they are be-
tween 0,41 and 0,90 and severely decreased when less than or equal to 0,40. 
These relative categories have prognostic value and offers prognostic data that are 
useful to predict limb survival, wound healing, and patient survival. 
From a systemic perspective, a reduced ABI is a potent predictor of the risk of fu-
ture cardiovascular events. This risk is related to the degree of reduction of the 
ABI, lower ABI predicts higher risk, and is independent of other standard risk fac-
tors. 
The presence of a severely decreased ABI thus identifies individuals who are at 
particularly high risk of subsequent development of rest pain, ischemic ulceration, 
or gangrene. For example, an ABI value greater than 0,50 suggests that progres-
sion to critical leg ischemia is unlikely during the subsequent 6,5 years of follow-
up. In contrast, when the ABI is less than 0,40, patients are more likely to experi-
ence ischemic rest pain
22
. 
In patients with PAD who do not have classic claudication a reduced ABI is high-
ly associated with reduced limb function. This is defined as reduced walking 
speed and a shortened walking distance during a timed 6-minute walk. The ABI 
can also serve as an aid in differential diagnosis, in those patients with exercise-
related leg pain of non-vascular causes which have a normal ankle pressure at rest 
and after exercise. 
In some patients with diabetes, renal insufficiency, or other diseases that cause 
vascular calcification, the tibial vessels at the ankle become non-compressible. 
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This leads to a false elevation of the ankle pressure. These patients typically have 
an ABI >1,40 and, in some of these patients, the doppler signal at the ankle cannot 
be obliterated even at cuff pressures of 300 mmHg. In these patients additional 
non-invasive diagnostic testing should be performed to evaluate the patient for 
PAD. Alternative tests include toe systolic pressures, pulse volume recordings, 
transcutaneous oxygen measurements or vascular imaging. When any of these 
tests is abnormal, a diagnosis of PAD can be reliably made. 
 
1.4.2. Toe-Brachial Index 
In individuals with noncompressible leg arterial segments, with an ABI greater 
than 1,3, the ABI is inadequate to make diagnosis of PAD. In such individuals, di-
agnostic information to establish the lower extremity PAD diagnosis can be ob-
tained by the measurement of toe systolic pressure and calculation of the toe-
brachial index, and toe-brachial index values less than 0,7 are usually considered 
diagnostic for lower extremity PAD. The toe pressure measurement remains a 
sensitive diagnostic test in such patients because digital arteries are usually spared 
the calcinosis that alters compressibility of more proximal arteries23. This test is 
performed by placement of a small occlusive cuff on the proximal portion of the 
great or second toe, with the return of toe pulsatility (which represents the systolic 
perfusion pressure) assessed by use of a plethysmographic detection device
1
. 
 
1.4.3. Continuous-Wave Doppler Ultrasound 
Continuous-wave Doppler ultrasound is used to obtain velocity waveforms and to 
measure systolic blood pressure at sequential segments of the lower extremities. 
Use of this technique permits initial estimation of disease location and severity, 
follow-up of disease progression, and quantitation of the effects of revasculariza-
tion therapies. One commonly used quantitative indirect measure for detection of 
proximal occlusive disease is the peak-to-peak pulsatility index, defined as the 
peak systolic velocity minus the minimum or most reversed diastolic velocity, di-
vided by the mean blood flow velocity. Normally, the pulsatility index increases 
19 
 
from the more proximal to the more distal segments of the lower extremities. A 
decrease in the pulsatility index between adjacent proximal and distal anatomic 
segments implies the presence of occlusive disease between these 2 locations
24
. 
The degree of decline in the pulsatility index value is usually proportional to the 
severity of occlusive disease. However, downstream from moderate stenosis, the 
velocity pulse waveform may revert to a normal waveform within a short dis-
tance, depending on the severity of stenosis. This latter phenomenon of “pulse 
normalization” distal to some arterial stenosis is a diagnostic limitation. Thus, the 
presence of a high-resistance-type waveform does not provide irrefutable evidence 
of the absence of more proximal occlusive disease
1,25
. Doppler waveform analysis 
can also provide useful localizing information in patients with poorly compressi-
ble arteries and in patients with a normal resting ABI. 
 
1.4.4. Exercise testing 
Exercise testing may be extremely useful: in establishing the diagnosis of lower 
extremity PAD when resting measures of the ABI are normal, to objectively doc-
ument the magnitude of symptom limitation in patients with lower extremity PAD 
and claudication, to objectively measure the functional improvement obtained in 
response to claudication interventions, and to individualize exercise prescriptions 
in patients with claudication before initiation of a formal program of exercise 
training. 
Exercise testing for patients with lower extremity PAD and claudication should 
use motorized treadmills programmed to provide less intense progressive work-
loads than are commonly used for healthy individuals or patients with coronary 
heart disease. The most common testing protocol is walking on a treadmill at 3,2 
km/h, 10% - 12% grade. The treadmill test should record the time of onset of leg 
symptoms, laterality and specific muscle groups involved, and the total walking 
time. During treadmill testing, the patient should be asked to indicate when any 
exercise-limiting symptoms occur; whether symptoms represent typical claudica-
tion, atypical limb discomfort, joint pain, or general fatigue; or if exercise is lim-
ited by chest pain or other cardiovascular symptoms. 
20 
 
Patients should be asked to walk to their maximally tolerated claudication symp-
tom to most accurately define peak walking time during treadmill exercise. 
Exercise should be stopped when mandated by symptoms or if objective signs of 
myocardial ischemia are observed. For patients who do not develop specific limb 
or cardiovascular symptoms, exercise may be terminated when patients achieve a 
high functional end point. 
After completing the test, the ABI is recorded while the patient is resting in the 
supine position. Measurement of the ankle blood pressure and the ABI at rest and 
immediately after exercise yields objective data to grade the dynamic functional 
significance of an arterial stenosis. Walking induces profound peripheral vasodila-
tation and decreased leg peripheral resistance. In normal individuals, the brachial 
and ankle blood pressures rise together and maintain their normal relationship 
with exertion. In contrast, in the presence of arterial occlusive disease, an abnor-
mal hemodynamic response results. In individuals with lower extremity PAD, de-
spite the increased central blood pressure, maximal exercise-induced ischemic 
vasodilation in the claudicating limb is associated with development of a signifi-
cant blood pressure gradient across the lower extremity arterial stenosis. Thus, in 
the individual with vasculogenic claudication, the post exercise ankle blood pres-
sure, and usually the ABI, will fall from their baseline value. A decrease in ABI of 
15% - 20% would be diagnostic of PAD
1,2
. 
Exercise ABI allows to individuate patients with pseudoclaudication due to other 
nonarterial functional limitation, that will demonstrate a normal post exercise 
ABI, and may be useful in establishing the diagnosis of lower extremity PAD 
when there is a high index of suspicion of lower extremity PAD, yet measures of 
the ABI at rest are normal. Both the absolute fall in post exercise ankle blood 
pressure and the percent fall in ABI value have been used as diagnostic criteria af-
ter exercise, with variable diagnostic thresholds
1
. 
A simplified form of exercise testing can utilize a pedal plantar flexion test when 
a treadmill is not available. In this test, patients are asked to stand flat-footed and 
perform 50 sequential, symptom limited ankle plantar flexions and thus raise the 
heels maximally off the floor. Post exercise ABI values measured with this “tip-
toe” test are similar to those recorded after treadmill exercise26.  
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An alternative test, which can be performed in patients with limitations to the use 
of treadmill testing, is corridor walking, such as that associated with the 6-minute 
walk test (6MWT). This test can potentially offer a more representative measure 
of walking ability during daily life and it is sensitive to change in walking endur-
ance after exercise interventions
27
. Thus, a 6MWT can serve as an alternative ob-
jective method of assessing walking endurance, for example in older men and 
women, who can associate treadmill walking performance with significant anxie-
ty
1
. 
In addition to clinical parameters, changes in the physical domains of the 36-item 
Short-Form Health Survey (SF-36) serve as patient-based measures of treatment 
effect
2
.  
 
1.5. Treatment 
The treatment for PAD include interventions to reduce cardiovascular and athero-
sclerotic risk factors, and those to limits the specific symptom of PAD, i. e. IC. To 
reduce adverse cardiovascular events associated with lower extremity PAD, life-
long treatment should include modification or elimination of atherosclerotic risk 
factors, such as cigarette smoking, diabetes mellitus, dyslipidemia, and hyperten-
sion, and promotion of daily exercise and use of a nonatherogenic diet. Patients 
with claudication are physically impaired and, therefore, the specific treatment 
goals are to relieve symptoms, improve exercise performance and daily functional 
abilities. 
 
1.5.1. Lipid lowering treatment 
Treatment of dyslipidemia reduces the risk of adverse cardiovascular events in pa-
tients with atherosclerosis. In patients with coronary artery disease, cholesterol 
lowering therapy with statin reduces the risk of nonfatal myocardial infarction and 
cardiovascular death by 24% to 34%
1,28,29
.  
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On the basis of these findings, it is recommended that patients with PAD and an 
LDL cholesterol level of 100 mg per dl or greater be treated with a statin. The 
recommended LDL cholesterol goal is less than 100 mg per dl, but when the risk 
is very high, an LDL cholesterol goal of less than 70 mg per dl is preferable
1
. This 
therapeutic option may also extend to patients with lower extremity PAD who are 
at very high risk and who have a baseline LDL cholesterol less than 100 mg per 
dl. 
 
1.5.2. Antihypertensive treatment 
For the antihypertensive therapy, which should be administered in patients with 
PAD, the current recommendation is a goal of 140/90 mmHg if the patient is 
nondiabetic, and 130/80 mmHg if the patient also has diabetes or renal insuffi-
ciency. This reduces the risk of myocardial infarction, ischemic stroke and vascu-
lar death
30,31
. 
Antihypertensive therapy may decrease limb perfusion pressure and potentially 
exacerbate symptoms of claudication or critical limb ischemia. These possibilities 
should be taken into consideration when administering antihypertensive drugs to 
patients with PAD. However, most patients are able to tolerate therapy without 
worsening of symptoms and should be treated appropriately to reduce the risk of 
adverse cardiovascular events. Beta-blockers and Angiotensin-converting enzyme 
inhibitors can be used, in patients with PAD, to reduce blood pressure without 
worsening in walking ability
1
.  
 
1.5.3. Diabetes therapies 
Aggressive treatment of diabetes does decrease the risk for microvascular events 
such as nephropathy and retinopathy
32,33
. Therefore, it is recommended
34
 that dia-
betic patients with lower extremity PAD be treated aggressively to reduce their 
glycosylated hemoglobin to less than 7%. Meticulous attention to foot care is nec-
essary to reduce the risk of skin ulceration, necrosis, and subsequent amputation. 
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This includes the use of appropriate footwear to avoid pressure injury, daily in-
spection and cleansing by the patient, the use of moisturizing cream to prevent 
dryness and fissuring
1,35
. 
 
1.5.4. Smoking cessation 
Individuals with lower extremity PAD who smoke cigarettes or use other forms of 
tobacco should be advised by each of their clinicians to stop smoking and should 
be offered comprehensive smoking cessation interventions, including behavior 
modification therapy, nicotine replacement therapy, or bupropion
1
. 
Observational studies have found that the risk of death, myocardial infarction, and 
amputation is substantially greater in those individuals with PAD who continue to 
smoke than in those who stop smoking
36,37
. 
In some but not all studies, exercise time is greater in patients who discontinue 
smoking than in current smokers
38,39
. 
Higher 1-year smoking cessation rates are achieved by physician advice coupled 
with frequent follow-up, approximately 5% compared with only 0,1% in those at-
tempting to quit smoking without a physician’s intervention40, and with pharma-
cological interventions
41
 such as nicotine replacement therapy and bupropion, re-
spectively 16% and 30%.  
 
1.5.5. Antiplatelet drug therapy 
Antiplatelet drug therapy in patients with PAD reduces the risk of myocardial in-
farction, ischemic stroke and vascular death. Aspirin in daily doses between 75 
and 325 mg is suggested as a safe and effective therapy, which leads to a 23% risk 
reduction. Higher doses of aspirin result in increased risk of gastrointestinal side 
effects and bleeding rates
1
. 
Clopidogrel, in dose 75 mg per day, is recommended as an effective alternative 
antiplatelet therapy to aspirin, and one study showed the better efficacy of this one 
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to reduce the risk of myocardial infarction, stroke, or vascular death in individuals 
with atherosclerotic lower extremity PAD
42
. 
Several studies have suggested that antiplatelet therapy, in addition to reducing 
the overall cardiovascular risk, may act specifically on PAD, reducing the risk of 
progression to arterial occlusion by 30% over a 19 month period
43
.  
 
1.5.6. Exercise and Lower Extremity PAD Rehabilitation 
Initial recommended treatment for patients with IC is a program of supervised ex-
ercise. Regular walking in a supervised claudication exercise program can be ex-
pected to result in an increase in the speed, distance, and duration walked, with 
decreased claudication symptoms at each workload or distance. These functional 
benefits accrue gradually and become evident over 4 to 8 weeks and increase pro-
gressively over 12 or more weeks.  
Unsupervised exercise or simple walking advice are not effective
44
. 
The data supporting the efficacy of supervised exercise programs to alleviate 
claudication symptoms are robust. Results showed that pain free walking time im-
proved by an average of 180% and maximal walking time increased by 120% (in-
terval between 74% and 230%) in claudication patients who underwent exercise 
training
45,46
. Exercise induced improvements in walking ability translate to an in-
crease of 38% in routine daily activity, as measured in one study by accelerome-
try
47
. Self-reported physical activity increased by 62%, which confirms that pa-
tients themselves appreciated this functional improvement
48
. In addition to the 
benefits of daily exercise on limb ischemic symptoms, regular exercise is associ-
ated with improved blood pressure, an improved serum lipid profile, including in-
creased HDL values and decreased triglyceride values, and improved glycemic 
control
49
. 
Such sustained increases in physical activity, if associated with improvements in 
cardiovascular risk factors, have the potential to reduce the risk of cardiovascular 
ischemic events, thereby potentially improving the poor prognosis for survival in 
this population. 
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Supervised exercise can induce increases in maximal walking ability that exceed 
those attained with drug therapies, which have been estimated to result in im-
provements in maximal walking distance of 20% to 25% with pentoxifylline 
and 40% to 60% with cilostazol
50,51
. 
The potential beneficial synergy of exercise training and pharmacological thera-
pies has been incompletely evaluated. Although there are biological reasons that 
could support potentially more rapid or sustained improvements in pain free or 
maximal walking distance when patients are treated concomitantly with exercise 
and claudication medications, there are currently inadequate data to support any 
efficacy conclusion
1
. 
Lack of responses to exercise and/or to drug therapy, or the presence of a stenosis 
in a proximal position, leads to the next level of intervention, which is limb revas-
cularization. 
Data confronting revascularization procedures, or arterial bypass, and exercise did 
not demonstrated superiority between each other. One recent multicenter study
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demonstrated the superiority of exercise, compared with stent placement, in in-
creasing total walking distance but not in increasing quality of life. It is likely that 
supervised exercise training can serve as a beneficial adjunct to further augment 
the improvements in walking that can be gained by both endovascular procedures 
and surgical bypass
53
. 
The data supporting the efficacy of supervised exercise programs to alleviate 
claudication symptoms are robust, therefore supervised exercise should be made 
available as part of the initial treatment for all patients with peripheral arterial dis-
ease. Many cardiac rehabilitation exercise programs can accommodate patients 
with claudication, providing an environment conducive for “lifestyle change” that 
underlies long-term compliance to exercise and risk factors modification. 
The biological mechanisms underlying such reproducible benefit are complex. 
However, there is inadequate evidence to attribute this functional benefit, as is of-
ten believed, to the growth of new collaterals (angiogenesis); in contrast, clinical 
improvement is more likely to be due to alterations in skeletal muscle metabolism, 
muscle hypertrophy, improvements in endothelial function, or altered gait
1
. 
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Because patients with claudication often have concomitant clinical or occult coro-
nary artery disease, hypertension and diabetes, adverse cardiovascular and physio-
logical responses during exercise training are possible, and this risk should be 
evaluated clinically before initiation of the therapeutic program. However, there is 
no evidence that patients with claudication need to undergo stress imaging or in-
vasive angiographic studies before initiating an exercise program.  
Such safety has been maintained, with serious adverse events rarely documented 
in clinical practice or in research investigations, by prudent application of an ini-
tial standard treadmill exercise test. This test should be performed with 12-lead 
electrocardiographic monitoring before a therapeutic exercise program is initiated, 
so that ischemic symptoms, ST–T-wave changes, or arrhythmias may be identi-
fied
1
. Although these patients will, by definition, have claudication-limited exer-
cise, and therefore will not achieve a true maximal exercise performance, the find-
ings from the exercise test can be used to determine that there are no untoward 
cardiovascular responses at the exercise level reached. The exercise test also pro-
vides information about claudication thresholds and heart rate and blood pressure 
responses for establishing an exercise prescription. 
Patient enrollment in a medically supervised exercise program with electrocardio-
graphic, heart rate, blood pressure, and blood glucose monitoring is encouraged. It 
is also prudent to use monitoring routinely during the initial exercise sessions; in-
dividual clinical responses then would determine the need for monitoring in sub-
sequent sessions. 
A typical supervised exercise program requires the performance of treadmill or 
track-based exercise for 45 to 60 minutes performed 3 or more times a week for a 
minimum of 12 weeks. Optimal workload is walking to near-maximal pain. 
The initial workload of the treadmill is set to a speed and grade that elicit claudi-
cation symptoms within 3 to 5 minutes. Patients are asked to continue to walk at 
this workload until they achieve claudication of moderate severity. This is fol-
lowed by a brief period of rest to permit symptoms to resolve. 
The exercise-rest-exercise cycle is repeated several times during the hour of su-
pervision. 
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This cycle of exercise and rest should last at least 35 minutes at the start of the 
program and increase to 50 minutes as the patient becomes comfortable with the 
exercise sessions. Workload should be modified in subsequent weeks, with an in-
crease in grade speed or both, to allow patients to reach an elevated pain free and 
total walking distance
45
.   
Typical benefits of such a program include an improvement in peak exercise per-
formance higher than 100%, significant improvements in walking speed and dis-
tance noted with the Walking Impairment Questionnaire and improvements in 
physical function and vitality on the SF-36 (36-item short-form health survey) 
questionnaire. 
 
1.6. Rational of the study                                                                                  
Whereas numerous studies demonstrated the key role of supervised exercise com-
pared to other exercise modalities, the best exercise typology is not equally well 
defined. 
Treadmill walking seems to be more effective than other exercise modalities, 
maybe because it reproduces walking activity performed in daily life.  
Former studies demonstrated that many patients with IC also have reduced muscle 
mass and a lack of muscle strength and endurance
54,55
, and modification in mus-
cles fibers composition
56
, which exacerbates their physical impairment
57
. They 
found indeed a link between muscle mass and peak VO2. 
One study
58
 also hypothesized a link between loss of muscle mass and the repeat-
ed exposition to ischemia-reperfusion during walking exercise. This may therefore 
also have negative effects on performance ability in subjects with PAD; similar 
negatives effects have been found on endothelial function
59
. 
Resistance training, is generally recommended for most individuals with other 
manifestations of cardiovascular disease because of its beneficial effects on 
strength and endurance, cardiovascular function, metabolism, coronary risk fac-
tors, and psychosocial wellbeing
60
. 
In healthy adults resistance training is used as a part of a program of general fit-
ness, and specially in elderly to prevent strength loss
61,62,63
. Subjects with PAD 
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have reduced balance and increased fall risk
64
, therefore they can benefit of re-
sistance training also for falls prevention. 
Nowadays few studies have been effectuated about resistance training as an alter-
native to walking on treadmill for subjects with PAD and results are con-
trasting
65,66
. There do not seem to be significant differences in the effect of the 
two different training modalities on walking ability, both pain free and total.  
Also few studies on combined training are available
67,58
, and none found positive 
results. This is surprising because combined training include walking on treadmill 
whose efficacy is proven. Lack of positives results may be due in the first case to 
different loads between control (only walking on treadmill) and combined group, 
indeed in the second case walking on treadmill was stopped at the onset of claudi-
cation pain, for author’s choice, and this made the different groups not fully com-
parable. 
For this reasons we decided to test the effects, on different aspects of physical 
function, of an experimental protocol of combined training, maintaining the same 
training loads on treadmill that are used nowadays in ours rehabilitative unit for 
standard training, and adding resistance training only for lower limbs. 
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2. MATHERIALS AND METODS 
  
2.1. Design of the study and inclusion criteria 
The study protocol consists in a non-randomized clinical trial, with 2 parallel arms 
(ratio1:1), with a follow-up period of di 3 months. 
The aim is to evaluate the superiority of a combined training protocol, walk plus 
strength exercise, with respect to that actually used, only walking and aerobic ex-
ercises, in improving walking endurance. 
Secondary aims are: to collect additional information about mechanisms leading 
to improvements in walking ability, and about effects of training, especially re-
sistance training, on some rarely studied aspects such as gait cycle variability and 
local oxygen extraction.  
To evaluate the effects on cardiovascular function, static and dynamic balance, 
fall risk and to study effects on muscular strength.  
Moreover effects on lipid profile, inflammation markers, daily physical activity 
and perceived quality of life will be evaluated. 
Subjects were divided into 2 groups, the one performing the experimental com-
bined protocol will be henceforth named strength group, the one performing the 
usual standard protocol will be henceforth named standard group. 
 
2.1.1. Inclusion criteria 
 clinical diagnosis of claudication intermittent (II stage of Leriche Fon-
taine’s classification, code ICD9 440.21) by anamnesis and visit with 
measurement of the Ankle Brachial Index, and diagnostic confirmation of 
presence of peripheral arterial disease by Eco color Doppler of lower 
limbs;  
 age between 40 and 80 years;  
 ABI between 0,5 e 0,9 in the symptomatic limb; 
 optimal control of hypertension, diabetes (glycated Hb<7%), dyslipidemia 
if presents. 
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2.1.2. Exclusion criteria 
 advanced diabetic microangiopathy with peripheral neuropathy;  
 acute myocardial infarction/stroke in the preceding 6 months;  
 surgical revascularization of the lower limbs in the preceding 6 months; 
 stable/unstable angina; 
 cardiac dysfunction (ejection fraction <45%);  
 renal impairment (creatinine >1.5 mg/dl);  
 respiratory disease reducing physical performance and exercise tolerance; 
 contraindications to exercise (for example orthopedic/neurologic patholo-
gy);  
 cancer in active phase;  
 severe depression. 
 
2.1.3. Criteria for ongoing exclusion  
 acute myocardial infarction/stroke; 
 onset of orthopedic pathology or other contraindications to exercise; 
 onset of cancer in active phase. 
 
2.2. Methods 
Each patient enrolled in the study was admitted to day hospital regime for three 
months, at the department of UOC Angiology/Vascular Rehabilitation of the gen-
eral hospital of Verona. Blood analysis were effectuated as usual at the beginning 
and at the end of the recovery period. 
Before being considered eligible for the enrolment in the study, patients under-
went a routine medical examination with ABI measure, to confirm the diagnosis 
of PAD and to assess the eligibility to undergo the protocol. They also performed 
a familiarization pre-treadmill test. At entry and after 12 weeks of training the fol-
lowing was done:  
 measure of weight, height, skinfolds, waist and hip circumference; 
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 ABI measure; 
 treadmill test with measure of: 
o heart rate; 
o oxygen consumption; 
o blood pressure; 
o local oxygen extraction; 
o gait cycle; 
 common femoral artery flow volume by Doppler, before and after tread-
mill test; 
 six minute walk test (6MWT); 
 strength test; 
 alternate step test; 
 unipedal stance test; 
 timed up and go; 
 short physical performance battery (SPPB); 
 SF-36 questionnaire; 
 chair sit and reach test; 
 daily physical activity monitoring; 
 blood analysis. 
 
2.2.1. Day 1 
Measure of weight, height, circumferences, skinfolds, compiling SF-36 question-
naire, treadmill test with laboratory examinations. 
 
2.2.1.1. Treadmill test  
Treadmill test was performed following standard protocol habitually used for in-
coming patients in the Unit of UOC Angiology/Vascular Rehabilitation, at con-
stant speed and slope (speed of 3,2 km/h and slope of 10%), according to guide-
lines. All subjects already effectuated a pre-test in our department of UOC Angi-
ology/Vascular Rehabilitation, to evaluate the possible occurrence of cardiovascu-
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lar symptoms and the ability to walk at speed and slope required by the test. For 
those who were not able to follow the protocol, slope and/or speed were reduced 
to enable them to perform it. Indeed for subjects that didn’t report any symptom 
during pre-test, speed was increased to 4,5 km/h and slope to 12%. 
During the test, patients were encouraged to walk with symptoms of claudication 
up to the maximum tolerable pain, they were also required to report immediately 
to the operator the appearance of the first symptoms, or of other inconvenience 
limiting performance, creating discomfort or indicating cardio-vascular fatigue for 
example: dyspnea, fatigue, chest or joint pain. 
By treadmill test we measured pain free walking distance (PFWD), which is the 
distance covered before the onset of claudication symptoms, and total walking 
distance (TWD), which is the total covered distance (for subjects that didn’t report 
pain PFWD were equal to TWD). Both measures are reported in meters and calcu-
lated from treadmill speed and time reported by the operator.  
During the test the evaluated parameters were constantly monitored. 
Basal values were calculated as mean of values of at least 30 seconds before the 
start of the test. 
Systolic and diastolic blood pressure were measured by Portapress®, and from the 
track provided by the instrument values at PFWD, which are the means of 
measures made in the 30 seconds before reaching the PFWD, and values at TWD, 
which are the means of measures made in the 30 seconds before the end of the 
test, were calculated. 
VO2 and respiratory quotient (R quotient VCO2/VO2, it indicates the energy 
source mainly used, with values around 1 indicating carbohydrates and values 
around 0,7 indicating fatty acids), the instrument also detects heart rate by the sig-
nal of the heart rate monitor. Values of these parameters at PFWD and TWD were 
calculated as mean of at least 15 breaths/beats preceding respective measures. 
Levels of oxygenated, deoxygenated, total and percentage of oxygenated hemo-
globin were recorded by NIRS in both calves. Values at TWD were calculated as 
mean of at least 30 seconds before the end of the test. 
The length of different phases of gait cycle was calculated by Optogait® over all 
the treadmill test. 
33 
 
Stride time is the duration of the whole gait cycle, it starts with the first contact of 
the heel of one foot with the floor and it ends with the subsequent contact of the 
same foot at the end of the gait cycle. Stance is the first phase of gait cycle, it in-
cludes the whole contact phase from the heel to the tip, swing is the second phase, 
during this phase the foot is raised and it is moving in the air. Both measures can 
be expressed as absolute values or as percentage of stride time. 
Usually the stance phase occupies about 60% and the swing phase 40% of stride 
time. As measure of gait, the variability coefficient of variation (CV) expressed as 
a percentage [(standard deviation/mean)*100] was calculated. Initial values were 
calculated as mean of at least 30 steps within those effectuated in the first minute 
of walk, final values were calculated as mean of at least 30 steps within those ef-
fectuated in the last minute of walk. 
Before starting and immediately after the test, flow volume of common femoral 
artery was measured bilaterally by Doppler. 
The measure was performed with the subject in the supine position, after a rest pe-
riod of 5 minutes for the initial assessment, at the level of the common femoral ar-
tery of each leg. The instrument automatically calculates diameter, speed and flow 
volume. Post exercise measures were performed immediately after the test end. 
We calculated the differences between post treadmill and basal values. 
 
2.2.1.2. Plicometry 
Thickness of subscapular, tricep, chest, axilla, suprailiac, abdominal, and thigh 
skinfolds was measured by a plicometer. Body density and percentage of fat mass 
(%FM) were evaluated by the equation of Jakson and Pollock on the basis of 7 
skinfolds, the equations are different for men and women. 
Body density for men = 1.112 – (0.00043499 * sum of 7 skinfolds) + (0.00000055 
* (square of the sum of 7 skinfolds)) – (0.00028826 * age). 
Body density for women = 1.097 – (0.00046971 * sum of 7 skinfolds) + 
(0.00000056 * (square of the sum of 7 skinfolds)) – (0.00012828 * age). 
%FM = (495/Body density) – 450. 
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2.2.1.3. Waist/hip ratio and body mass index 
Body mass index (BMI) is calculated by dividing the individual’s weight in kilo-
grams by height in meters squared. It is widely accepted that being overweight, 
traditionally defined as having a BMI >25 kg/m2, is a major risk factor for a wide 
range of chronic diseases and injuries including cardiovascular disease, type II di-
abetes, and certain site-specific cancers
68
. A reductions in life expectancy by 3 
years in individuals with moderate obesity (BMI 30–35 kg/m2), and up to 10 years 
in individuals with extreme obesity (BMI 40–50 kg/m2) is estimated69, the latter 
being equivalent to the years lost by lifetime smoking. 
Waist/hip ratio (WHR) is calculated by dividing the waist circumference by that 
of the hip. Abdominal obesity assessed by this index is related to increased risk of 
all-cause mortality throughout the range of body mass index
70
. The waist/hip ratio 
seems to be better than BMI in predicting cardiovascular risk. Cut off value of 
WHR is 0,8 for women and 0,9 for men. 
 
2.2.2. Day 2 
Six minute walk test (6MWT), test included in short physical performance battery 
(SPPB), alternate step test, timed up and go, balance on force plates, joint mobili-
ty.  
 
2.2.2.1. Six minute walk test (6MWT) 
By six-minute walk test we measured pain free walking distance (PFWD) and to-
tal walking distance (TWD). 
This test is easy to perform and does not require special equipment. It requires a 
stopwatch, a measurement tape, and cones to mark the path. The subjects has to 
cover back and forth, as many times as possible, the 30 meter corridor in the 6 
minutes allowed. At the end of the six minutes, the distance covered in meters is 
measured. Moreover, patients with PAD era asked to report the onset of pain to 
measure the pain free walking distance. During the test the subjects walks at the 
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self-selected speed, nonetheless, before starting participants are advised that the 
goal of the 6MWT is to achieve the greatest distance possible, and therefore they 
should walk as fast as possible. Participants are allowed to rest during the test, but 
the clock continues to run while the participant rests. If the patient usually uses 
any gait aid during ambulation, such for example a cane, he can use it also during 
the test. 
6MWT provides measures similar to those obtained during the treadmill tests, 
however, we decided to do this additional evaluation because walking on a tread-
mill requires dynamic balance and the ability to maintain a constant rhythmic gait 
in order to keep up with the treadmill’s constant pace. Patients with PAD have 
specific impairments in balance and cognitive function that are likely to make the 
need for good balance and a rhythmic gait on the treadmill particularly difficult to 
achieve, therefore they frequently touch or hold on to the treadmill rail to maintain 
balance. Importantly, these skills are intrinsically linked to treadmill walking but 
do not apply to walking in daily life. Furthermore, among patients with PAD, 
handrail support is associated with a greater learning effect and longer maximal 
walking distances, compared to no handrail support
71
.  
In a corridor walk, such as the six-minute walk test, PAD patients who have diffi-
culty walking can slow down, but keep going or even rest temporarily without 
stopping the test. In contrast, the treadmill test requires PAD participants to main-
tain or even increase their walking speed. PAD participants who cannot keep up 
with the treadmill must stop walking, thereby simultaneously ending the treadmill 
test. This is likely to result in longer walking distances in the six-minute walk than 
on the treadmill. 
Another limitation of treadmill walking is that it is associated with a significant 
learning effect. Even without any therapeutic intervention, patients with PAD typ-
ically increase their maximum and pain-free walking distance between baseline 
and follow-up testing.  
The extent of the improvement only due to learning effect has been estimated
71
 
between 17% and 26%. In contrast there aren’t learning effects by repeating the 
6MWT. 
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Among patients with PAD, the 6MWT detects and quantifies improvements due 
to a training cycle, or declines in walking endurance due to the worsening of the 
disease. Also a baseline 6MWT predicts rates of all-cause mortality, cardiovascu-
lar disease mortality, and mobility loss. Some studies, effectuated on both healthy 
subjects or patients, demonstrated the clinical meaningfulness of changes in 
6MWT. A small meaningful change was defined as a change over 20 meters and a 
large meaningful change in 6MWT was defined as a change of 50 meters
71
. 
Furthermore, during treadmill test performed for our protocol, the subject would 
have been linked to numerous monitoring devices, which could accentuate the 
discomfort of the test. 
For these reasons, we decided to assume results of 6MWT as reference to evaluate 
the effects of our training protocol, besides the traditional treadmill evaluation. 
. 
2.2.2.2. Timed up and go 
Timed up and go is a test of physical function which correlates well with activities 
in daily life
72
 and is often used in elderly to evaluate fall risk. The test consists in 
rising from an arm chair, walk 3 meters, turn, walk back, and sit down again. 
Time employed from the “start” to when the subject is again properly seated, with 
his back against the chair, is timed. The patient may use any gait aid that he nor-
mally use during ambulation. 
In addition to the time spent, we also record whether the subject has uncertainties 
in gait, loses his balance, makes short steps, holds on to the wall, doesn’t move his 
arms, turns with a jerky motion, or doesn’t use the aids correctly. The subject 
should be given a practice trial that is not timed before testing. The reference val-
ues for the time spent in test execution vary according to age, for the range 60-69 
years they are comprised between 7,1 and 9 seconds with mean 8,1 seconds. 
 
 
 
37 
 
2.2.2.3. Alternate step test 
Alternate step test is a test of dynamic balance which involves weight shifting and 
provides a measure of lateral stability. This test involves alternatively placing the 
entire left and right feet (shoes removed) as fast as possible onto a step that is 18 
cm high and 40 cm deep. The time taken to complete eight steps, alternating be-
tween the left and right feet represents the test measure. Results obtained in this 
test were demonstrated to be significantly worse in patients who subsequent fell
73
. 
The cut off value between fall risk and normal subjects is 10 seconds.  
 
2.2.2.4. Protocols of test on force plates 
Static balance test was performed on force plates. It supplies additional infor-
mation on displacements of the center of pressure (CoP). 
 
2.2.2.4.1. Romberg test 
This test includes 4 tasks with increasing level of difficulty. 
The first level requires subject standing in an upright position with feet closed and 
eyes open for 10 seconds without swaying while holding both arms extended to 
the front with palms facing upward. 
The second level requires subject standing in the same position, but with eyes 
closed. 
The third level requires eyes open and feet in tandem stand, the tip of one foot in 
contact with the heel of the other. 
The forth level is equal to the third but with eyes closed. 
It is observed whether the subject is able to maintain the position for 10 seconds 
without moving his feet, lowering his arms or opening his eyes in the levels that 
provide eyes closed. 
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2.2.2.4.2. Unipedal stance test 
Unipedal stance test is a test of unipedal balance. Subject were asked to maintain 
unipedal stance for as long as possible, they chose the leg they preferred for the 
test. The tip of the raised foot is about at the height of the contralateral ankle. The 
test is interrupted if the patient shifts the stance foot, places the lifted foot on the 
floor or moves the arms. The test was stopped and considered normal if it reached 
45 seconds. Subjects were given three trials, and the longest one was considered, 
unless they achieved 45 seconds on the first or second trial. Results shorter than 
30 seconds were demonstrated to be linked with an elevated fall risk, whereas 
those longer than 30 seconds were associated with low risk
74
. 
 
2.2.2.5. SPPB (Short Physical Performance Battery) 
The SPPB scale is a short battery of tests established to evaluate the functionality 
of the lower limbs. 
It consists in three sections: balance, walking speed and dynamic balance/strength 
of the lower limbs. 
 The assessment of the balance is composed of three tests: 
o standing in an upright position with feet closed for 10 seconds; 
o standing in an upright position with feet in semi-tandem position, the big 
toe of one foot beside the heel of the other, for 10 seconds; 
o standing in an upright position with feet in tandem position, the tip of one 
foot in contact with the heel of the other, always for 10 seconds. 
The score of this section goes from a minimum of 0, if the patient is not able to 
stand with feet closed for at least 10 seconds, to a maximum of 4, if he can suc-
cessfully complete the three tests.  
 The second test is designed to assess the walking speed on 4 linear meters. 
The score of this section varies, on the basis of the time realized, from 0 if unable, 
to 1 if the performance lasts longer than 8,7 seconds, to a maximum of 4 if he can 
perform the task in less than 4,8 seconds. 
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 The third section evaluates the time taken to perform 5 times consecutive-
ly the sit to stand from a chair, without using the upper limbs, which must 
be crossed on the chest. 
Also in this case the score goes from 0 if unable, or if the performance lasts longer 
than 60 seconds, to a maximum of 4 if it lasts less than 11,2 seconds. 
The total score of the scale has therefore a range from 0 to 12.  
 
2.2.2.6. Chair sit and reach 
As a measure of joint mobility we utilized the chair sit and reach (CSR), a modi-
fied version of the sit and reach test. During the test the subject sits on the edge of 
a chair (placed against a wall for safety). One foot must remain flat on the floor. 
The other leg is extended forward with the knee straight, heel on the floor, and 
ankle bent at 90°. With one hand placed on top of the other with tips of the middle 
fingers even, the subject tries to reach forward toward the toes by bending at the 
hip, keeping the back and the knee straight and head up. The distance is measured 
between the tip of the fingertips and the toes. If the fingertips do not touch the 
score is negative, if they touch the toes the score is zero, if they overlap the score 
is positive. This test in older adults produces reasonably accurate and stable 
measures of hamstring and lower back flexibility. In addition, it appears to be saf-
er and more comfortable to perform compared to the traditional floor sit-and-reach 
tests
75
.  
 
2.2.3. Day 3 
 
2.2.3.1. Strength test 
Strength was measured with the exercises that later would been part of the train-
ing protocol: leg press, leg extension, leg curl, hip abduction, hip adduction, 
and calf press. 
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Maximal dynamic strength (1-RM) was evaluated by indirect estimation and cal-
culated by the formula of Brzycki on the basis of 10 repetitions
76
. 
During the test the subject performed for each exercise two series of warming and 
familiarization with a light weight. After a complete recovery we proceed with the 
test series, up to find out the load with which the subject was not able to make a 
number of repetitions exceeding 10. Between the series a complete recovery time 
of 3 minutes was observed. The same delay was provided between different exer-
cises. 
The most reliable method to evaluate the maximal dynamic strength of a muscle, 
or a group of muscles, is the test of 1 maximal repetition (1-RM). However un-
trained subjects may not be able to reach their 1-RM, therefore this test can be 
contraindicated for those who have no previous experience of weight lifting. 
Therefore in clinical practice, when performing tests of muscle strength in patients 
with low fitness condition, methods that indirectly estimate the maximal are pref-
erable to 1-RM test. 
Procedures for the estimation of 1-RM are reported in the literature, and their va-
lidity has been demonstrated for exercises such as squat, triceps press, bicep curl, 
leg press, hip flexion, hip extension, hip abduction, hip adduction, plantar flexion, 
and dorsiflexion
77
. There are various formulas for the estimation of 1-RM, among 
these the equation of Brzycki, which is commonly used for the estimation of 1-
RM by a submaximal exercise of repetition (5-8 RM test), was demonstrated
78
 to 
be the most reliable for the evaluation of 1-RM in the bench press exercise (r= 
0,98), if the maximal number of repetitions during the test doesn’t exceeds 10. 
This formula demonstrated to be reliable even if used in untrained or diseased 
subjects
77
. The equation used in the calculation is as follows: 1RM = W/[102.78– 
2.78(R)]/100 with W = weight lifted and R = number of repetitions effectuated.  
 
2.2.4. Measure of daily activity 
Patients wore an Armband® bracelet for a week. The device was placed according 
to the manufacturer instructions on the left triceps. This device measures biaxial 
acceleration, temperature and impedance, and through a series of algorithms it is 
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able to calculate the duration of daily physical activity, number of steps and to es-
timate the energy expenditure. This device was demonstrated to be reliable in as-
sessing these data for low intensity activities of daily life
79
. 
 
2.2.5. Training protocols 
 
2.2.5.1. Training protocol of the strength group 
Training was performed 3 times a week, with sessions lasting 1 hour and 30 
minutes, subdivided into about 30 minutes of walking on the treadmill and 1 hour 
of exercises with strength machines. We utilized 6 training machines: leg exten-
sion, leg curl, hip abduction, hip abduction, leg press, leg press for calves. For 
each exercise 3 sets of 10 repetitions were performed, with load of 70% of 1-RM. 
The load was monitored weekly and adjusted when the subject was able to per-
form more than 12 reps with the previous load. Between the series, and between 
the different exercises, a recovery period of 2 minutes was observed. The workout 
on the treadmill required walking until reaching a moderate pain, followed by rest 
until the pain resolution. The cycle was repeated 2-3 times. Workouts with ma-
chines and with treadmill were alternated, always respecting recovery periods. 
 
2.2.5.2. Training protocol of the standard group 
The workout on the treadmill required walking until reaching a moderate pain, 
followed by rest until the pain resolution. The cycle was repeated 2-3 times, as for 
the strength group. Also 40 minutes of light free body gymnastics and 20 minutes 
of winding-down cycling were performed. 
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2.3. Materials 
The equipment available at the our Division and at the laboratories of Sports Sci-
ence Faculty includes: 
• Color Doppler Ultrasound GE Healthcare, model Vivid 7 Pro, with probes 
10L, M4S, 4C, that we use to perform cardiac Doppler ultrasound examina-
tions and those of the vessels of the lower limbs and carotids;  
• Color Doppler Ultrasound Acuson, Sequoia 512 (Imagegate), with probes 
3V2c, 8L5, 15L8w, that we use to perform ecocolordoppler of the vessels of 
the lower limbs and carotids; 
• Doppler Basic S, Basicare 120032, that we use to measure ABI;  
• Portapres Model-2 with data analysis software BeatScope 1.1 0344 CE Fin-
apres Medical Systems Enschede, PH, Netherlands, to monitor beats to 
beats finger blood pressure; 
• Quark PFT 0476 CE Cosmed Rome, RM, Italy, to monitor breath to breath 
respiratory exanges; 
• Oxiplex ISS Near Infrared Tissue Oximeter Model 95306 with software Ox-
iTS 3.1 for measuring the concentration of oxygenated/deoxygenated hemo-
globin in the peripheral circulation; 
• Plicometer GIMA, MI, Italy, for plicometry; 
• Tredmill Runrace Technogym 770 CE to effettuate test and training; 
• Macchines for strength training; 
• Armband SenseWear Pro-3 version 6.1, BodyMedia, Pittsburgh, PA, USA. 
 
2.3.1. Portapress 
Portapress is a device which is able to monitor, beat to beat, the pressure wave 
form, and to derive systolic and diastolic pressure values, heart rate and to calcu-
late other parameters, such as total peripheral resistances and cardiac output. 
By an inflatable finger cuff, which comprises an infrared plethysmograph, appro-
priately sized to the patient’s finger and placed around the medial phalanx of the 
index or the middle finger, the device measures blood pressure variations. The de-
43 
 
vice automatically calibrates itself in about 1 minute at the beginnings of registra-
tion, and recalibrate, if necessary, during the test for few seconds, at approximate-
ly one-minute intervals. Blood pressure measured in fingers and in central arteries 
have different values, differences by -0,8 ± 11,7 mmHg for systolic pressure and 
by -1,6 ± 7,7 mmHg for diastolic pressure are estimated
80
. 
 
2.3.2. NIRS 
NIRS is a device consisting of two pulsed light sources and two detectors ava-
lanche photodiode. It uses intensity-modulated light at a frequency of 1 MHz and 
laser diodes at three wavelengths (905, 850 and 770 nm) corresponding to high 
absorption of oxyhemoglobin and deoxyhemoglobin. When near-infrared light 
propagates through biological tissues, it is partly absorbed or scattered by the tis-
sues and partly recollected by the detector. The intensity of the recollected light 
provides information about oxyhemoglobin and deoxyhemoglobin concentrations. 
The device was switched on at least 30 minutes before the beginnings of the test 
and properly calibrated through a known absorption block. During the test one 
probe for each leg was secured to the medial side of the calf by fabric bands, and 
suitably covered with bandages to isolate it from the ambient light. In addition to 
the oxygenated and deoxygenated hemoglobin the instrument automatically calcu-
lates the total hemoglobin, which is the sum of the two, and the percentage of ox-
ygenated hemoglobin. 
 
2.3.3. Quark 
Quark is a device that analyzes oxygen consumption and ventilation, through an 
appropriate size mask connected to a turbine and a sensor. The device was 
switched on at least 30 minutes before the beginnings of the test and properly cal-
ibrated through a gas sample of known concentration and the use of a three liter 
syringe. 
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2.3.4. Optogait 
Optogait is an optical detection system consisting of two bars, a transmitter and a 
receiver one. The bars communicate between them via infrared light, through 96 
LEDs. Interruption of the contact between the bars are detected, and allow to cal-
culate the contact and the flight time during walking, with a time resolution of one 
thousandth of a second and a spatial resolution of one centimeter. The instrument 
is set with parameters of treadmill’s speed and length of the subject's foot and 
doesn’t require calibrations. 
 
2.4. Statistical analysis 
For statistical analysis we utilized SPSS Software version16.0 for Windows.  
We performed analysis per protocol, so the 2 subjects who didn’t completed the 
trial were excluded from the analysis. To exclude differences in baseline data we 
performed Student's t-tests for independent samples, or the Wilcoxon test, accord-
ing to the type of data to analyze. We used Fischer's exact test to assess differ-
ences in the presence of diseases and in the number of smokers. Differences be-
tween groups pre – post training were analyzed by ANOVA test, Wilcoxon’s test 
for nonparametric data or  Student’s t-test for paired data. 
The differences are significant if p≤0,05. 
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3. RESULTS 
 
3.1. Characterization of the patients 
24 patient affected by peripheral arterial disease satisfying inclusion criteria were 
enrolled into the study: 12 subjects were assigned to the standard group, and 12 to 
the strength group. In the baseline condition, the patients of the two groups dif-
fered by age, however there were no differences in the presence of various diseas-
es, the number of smokers, in walking ability, and in none of the studied parame-
ters. 2 subjects of the strength group were excluded during the study, respectively 
for non-compliance and for an incoming disease that prevented the workout. 
 
 
 Patients strength group 
n= 12 
Patients standard group 
n= 12 
Lost at follow-up 2 0 
Men/Women 11/1 11/1 
Age 49 – 74yo 59 – 77yo 
Height  172 ± 6cm 168 ± 6cm 
Smokers 3 2 
Ex-smokers 5 9 
Diabetes 4 8 
Hypertension 6 10 
Dyslipidemia 2 4 
Table 1: baseline conditions of patients. 
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Variations after 36 training sessions:   
 
 Forza Standard 
 pre allena-
mento 
post allena-
mento 
pre allena-
mento 
post allena-
mento 
Weight 81 ± 9kg 80 ± 8kg* 85 ± 20kg 85 ± 20kg 
BMI 28 ± 4kg/cm² 27 ± 3kg/cm² 30 ± 6kg/cm² 30 ± 6kg/cm² 
%FM 35 ± 8% 33 ± 9*% 33 ± 12% 35 ± 10% 
WHR 1,0 ± 0,04 0,9 ± 0,06 1,0 ± 0,06 1,0 ± 0,04 
CSR -9 ± 8cm -5 ± 10cm* -16 ± 9cm -14 ± 11cm 
Table 2: body composition and joint mobility * difference pre-post training p<0,05. 
 
3.2. Data about walking 
 
 
3.2.1. Data of 6 minute walk test 
 
Graph 1: mean of pain free walking distance as measured by 6MWT, * between groups in-
teraction p<0,05. 
 
*
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Graph 2: mean of total walking distance as measured by 6MWT, # p<0,05 for time factor. 
 
 
Graph 3: mean of percentage of pain free on total walking distance during 6MWT. 
 
The mean of the values of pain free walking distance, measured by 6MWT, sig-
nificantly increased in the strength group from 276 ± 96 meters to 390 ± 77 me-
# 
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ters, whereas in the standard group it increased from 297 ± 99 meters to 303 ± 118 
meters. 
The mean of the values of total walking distance significantly increased in time, 
from 436 ± 68 meters to 465 ± 62 meters in the strength group, and from 399 ± 60 
meters to 420 ± 71 meters in the standard group. 
The mean of percentage of pain free on total walking distance increased in the 
strength group from 66 ± 25 % to 81 ± 25 %, whereas in the standard group it de-
creased from 74 ± 22 % to 73 ± 25 %.  
 
 
3.2.2. Data of treadmill test 
 
Graph 4: mean of pain free walking distance as measured by treadmill test, * between 
groups interaction p<0,05. 
 
* 
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Graph 5: mean of total walking distance as measured by treadmill test, # p<0,05 for time fac-
tor. 
 
 
Graph 6: mean of percentage of pain free on total walking distance during treadmill test. 
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The mean of the values of pain free walking distance, measured by treadmill test, 
significantly increased in the strength group from 302 ± 245 meters to 535 ± 429 
meters, whereas in the standard group it increased from 330 ± 240 meters to 376 ± 
236 meters.  
The mean of the values of total walking distance significantly increased in time, 
from 674 ± 382 meters to 756 ± 309 meters in the strength group, and from 434 ± 
255 meters to 573 ± 252 meters in the standard group.  
The mean of percentage of pain free on total walking distance increased in the 
strength group from 55 ± 27 % to 74 ± 36 %, whereas in the standard group it re-
mained unchanged from 70 ± 16 % to 70 ± 22 %. 
 
3.3. Data about blood pressure 
 
Graph 7: mean of systolic blood pressure at rest, # p<0,05 for time factor. 
 
The mean of the values of systolic blood pressure at rest significantly decreased in 
time, from 137 ± 33 to 114 ± 32 mmHg in the strength group, and from 128 ± 26 
to 112 ± 21 mmHg in the standard group.  
 
# 
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Graph 8: mean of systolic blood pressure measured at the end of pain free walking distance 
by treadmill test, ∆ significance trend for between groups interaction p= 0,057. 
 
 
Graph 9: mean of diastolic blood pressure measured at the end of pain free walking distance 
by treadmill test, * between groups interaction p<0,05. 
 
 
∆ 
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Graph 10: mean of systolic blood pressure measured at the end of treadmill test, * between 
groups interaction p<0,05. 
 
 
Graph 11: mean of diastolic blood pressure measured at the end of treadmill test, * between 
groups interaction p<0,05. 
 
The mean of the values of systolic blood pressure, measured in the last minute of 
pain free walking distance by the treadmill test, decreased in the strength group 
* 
* 
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with a significant trend from 193 ± 52 mmHg to ± 164 ± 34 mmHg, whereas in 
the standard group it increased from 146 ± 35 mmHg to 151 ± 25 mmHg. 
The mean of the values of diastolic blood pressure, measured in the last minute of 
pain free walking distance by the treadmill test, decreased significantly in the 
strength group from 83 ± 34 mmHg to 59 ± 23 mmHg, whereas in the standard 
group it increased from 54 ± 15 mmHg to 61 ± 17 mmHg. 
The mean of the values of systolic blood pressure, measured in the last minute of 
total walking distance by the treadmill test, decreased significantly in the strength 
group from 190 ± 46 mmHg to 162 ± 34 mmHg, whereas in the standard group it 
increased from 153 ± 20 to 155 ± 23 mmHg. 
The mean of the values of diastolic blood pressure, measured in the last minute of 
total walking distance by the treadmill test, decreased significantly in the strength 
group from 87 ± 36 mmHg to 62 ± 23 mmHg whereas in the standard group it de-
creased from 65 ± 18 mmHg to 63 ± 13 mmHg. 
 
3.4. Data about heart rate 
 
Graph 12: mean of heart rate at rest, # p<0,05 for time factor. 
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Graph 13: mean of heart rate measured at the end of pain free walking distance by treadmill 
test, * between groups interaction p<0,05. 
 
 
Graph 14: mean of heart rate measured at the end of treadmill test, * between groups inter-
action p<0,05. 
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The mean of the values of heart rate at rest significantly decreased in time, from 
82 ± 12 bpm to 76 ± 12 bpm in the strength group, and from 73 ± 13 bpm to 70 ± 
10  bpm in the standard group. 
The mean of the values of heart rate, measured in the last minute of pain free 
walking distance by the treadmill test, significantly decreased in the strength 
group from 113 ± 27 bpm to 108 ± 24 bpm, whereas in the standard group it in-
creased from 92 ± 18 bpm to 104 ± 19 bpm. 
The mean of the values of heart rate, measured in the last minute of total walking 
distance by the treadmill test, significantly decreased in the strength group from 
121 ± 28 bpm to 112 ± 23 bpm, whereas in the standard group it increased from 
97 ± 16 bpm to 107 ± 19 bpm. 
 
3.5. Data about oxygen consumption 
 
Graph 15: mean of VO2 measured at the end of pain free walking distance by treadmill test, 
∆ significance trend for between groups interaction p= 0,059. 
∆ 
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Graph 16: mean of VO2 measured at the end of treadmill test, * between groups interaction 
p<0,05. 
 
 
Graph 17: mean of respiratory quotient at the end of treadmill test, # p<0,05 for time factor. 
 
* 
# 
57 
 
The mean of the values of VO2, measured in the last minute of pain free walking 
distance by the treadmill test, decreased in the strength group with a significant 
trend from 1339 ± 372 ml/min to 1227 ± 281 ml/min, whereas in the standard 
group it increased from 1122 ± 213 ml/min to 1162 ± 229 ml/min. 
The mean of the values of VO2, measured in the last minute of total walking dis-
tance by the treadmill test, significantly decreased in the strength group from 1473 
± 369 ml/min to 1276 ± 264 ml/min, whereas in the standard group it decreased 
from 1188 ± 226 ml/min to 1171 ± 246 ml/min. 
The mean of the values of the respiratory quotient, measured in the last minute of 
total walking distance by the treadmill test, significantly increased in time, from 
0,91 ± 0,04 to 1 ± 0,08 in the strength group, and from 0,89 ± 0,06 a 0,97 ± 0,09 
in the standard group. 
 
3.6. Data about local oxygenation  
 
Graph 18: mean of deoxyhemoglobin at the end of treadmill test, * between groups interac-
tion p<0,05. 
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Graph 19: mean of oxyhemoglobin at the end treadmill test, # p<0,05 for time factor. 
 
 
Graph 20: mean of percentage of oxyhemoglobin at the end of treadmill test, # p<0,05 for 
time factor. 
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Graph 21: mean of total hemoglobin at the end of treadmill test. 
 
The mean of the values of deoxyhemoglobin, measured in the last minute of total 
walking distance by the treadmill test, significantly increased in the strength group 
from 33 ± 14 to 41 ± 9, whereas in the standard group it decreased from 42 ± 10 
to 39 ± 14. 
The mean of the values of oxyhemoglobin, measured in the last minute of total 
walking distance by the treadmill test, significantly increased in time, from 37 ± 
12 to 49 ± 12 in the strength group, and from 37 ± 7 to 41 ± 12 in the standard 
group. 
The mean of the percentage of oxyhemoglobin, measured in the last minute of to-
tal walking distance by the treadmill test, significantly increased in time, from 50 
± 11 % to 58 ± 9 % in the strength group, and from 49 ± 7 % to 52 ± 11 % in the 
standard group. 
The mean of the values of total hemoglobin, measured in the last minute of total 
walking distance by the treadmill test, increased  in the strength from 69 ± 23 to 
80 ± 15, whereas in the standard group it increased from 74 ± 9 to 79 ± 27. 
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3.7. Data about flow volume 
 
Graph 22: mean of the difference between flow volume before and after  treadmill test, * be-
tween groups interaction p<0,05. 
 
The mean of the differences between values of flow volume measured before and 
after the treadmill test significantly increased in the strength group from 54 ± 31 
to 133 ± 88, whereas in the standard group it decreased from 75 ± 81 to 69 ± 102. 
 
3.8. Data about strength 
The mean of the values of maximal strength estimated by the leg press significant-
ly increased in the strength group from 187 ± 54 kg to 292 ± 59 kg, whereas in the 
standard group it increased from 151 ± 65 kg to 153± 47 kg. 
The mean of the values of maximal strength estimated by the leg extension signif-
icantly increased in the strength group from 47 ± 14 kg to 78 ± 13 kg, whereas in 
the standard group it increased from 35 ± 12 kg to 40 ± 12 kg. 
The mean of the values of maximal strength estimated by the leg curl significantly 
increased in the strength group from 54 ± 15 kg to 83 ± 8 kg, whereas in the 
standard group it increased from 43 ± 14 kg to 46 ± 12 kg. 
* 
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The mean of the values of maximal strength estimated by the hip abduction signif-
icantly increased in the strength group from 72 ± 18 kg to 100 ± 15 kg, whereas in 
the standard group it remained unchanged from 61 ± 19 kg to 61 ± 17 kg. 
The mean of the values of maximal strength estimated by the hip adduction signif-
icantly increased in the strength group from 58 ±18 kg to 95 ± 18, whereas in the 
standard group it increased from 49 ±13 kg to 56 ± 17 kg. 
The mean of the values of maximal strength estimated by the leg press for calves 
significantly increased in the strength group from 175 ± 43 kg to 258 ± 62 kg, 
whereas in the standard group it increased from 121 ± 32 kg to 133 ± 40 kg. 
 
 
 
Graph 23: mean of load estimated for 1RM on the leg extension, * between groups interaction 
p<0,05. 
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Graph 24: mean of load estimated for 1RM on the  leg curl, * between groups interaction p<0,05. 
 
 
Graph 25: mean of load estimated for 1RM on the  leg press, * between groups interaction p<0,05. 
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Graph 26: mean of load estimated for 1RM on the  leg press for calves, * between groups in-
teraction p<0,05. 
 
 
 
Graph 27: mean of load estimated for 1RM on the hip abduction, * between groups interac-
tion p<0,05. 
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Graph 28: mean of load estimated for 1RM on the hip adduction, * between groups interac-
tion p<0,05. 
 
3.9. Data about blood parameters 
 
Graph 29: mean of total cholesterol, * between groups interaction p<0,05. 
 
* 
* 
65 
 
 
Graph 30: mean of triglycerides, * between groups interaction p<0,05. 
 
 
 
Graph 31: mean of fibrinogen, * between groups interaction p<0,05. 
 
 
* 
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Graph 32: mean of erythrocytes segmentation rate, * between groups interaction p<0,05. 
 
 
Graph 33: mean of homocysteine. 
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The mean of the values of  total cholesterol significantly decreased in the strength 
group from 163 ± 25 mg/dl to 146 ± 17 mg/dl, whereas in the standard group it 
increased from 146 ± 20 mg/dl to 152 ± 28 mg/dl. 
The mean of the values of triglycerides significantly decreased in the strength 
group from 149 ± 93 mg/dl to 94 ± 39 mg/dl, whereas in the standard group it in-
creased from 141 ± 62 to 153 ± 75 mg/dl. 
The mean of the values of erythrocytes segmentation rate (ESR) increased in the 
strength group from 23 ± 16 mm to 24 ± 19 mm, whereas it significantly de-
creased in the standard group from 43 ± 17 mm to 35 ± 17 mm. 
The mean of the values of fibrinogen increased in the strength group from 2,6 ± 
0,6 g/L to 2,9 ± 0,6 g/L, whereas it significantly decreased in the standard group 
from 3,5 ± 0,9 g/L to 3,1 ± 0,6 g/L. 
The mean of the values of homocysteine increased in the strength group from 1,84 
± 0,5 mg/dl to 1,95 ± 0,6 mg/dl, whereas it decreased in the standard group from 
2,68 ± 1,2 mg/dl to 2,4 ± 0,6 mg/dl. 
 
3.10. Data about physical activity in daily life 
 
Graph 34: mean of  daily taken steps, * between groups interaction p<0,05. 
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Graph 35: mean of the duration of daily physical activity. 
 
 
Graph 36: mean of daily active energy expenditure for activities over moderate intensity. 
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The mean of number of daily steps significantly increased in the strength group 
from 8946 ± 3046 to 10809 ± 3981, whereas in the standard group it increased 
from 6331 ± 2445 to 6507 ± 2680.  
The mean of the duration of daily physical activity increased in the strength group 
from 100 ± 86 minutes to 115 ± 120 minutes, whereas in the standard group it in-
creased from 49 ± 40 minutes to 53 ± 30 minutes. 
The mean of the values of  daily active energy expenditure increased in the 
strength group from 1939 ± 1558 joule to 2247 ± 2095 joule, whereas in the 
standard group it increased from 1187 ± 1269 joule to 1325 ± 1179 joule. 
 
3.11. Data about force plates 
 
 
Graph 37: mean of the area of the ellipse described by CoP in Romberg’s condition. 
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Graph 38: mean of the area of the ellipse described by CoP in Romberg’s condition eyes 
closed, * between groups interaction p<0,05. 
 
 
Graph 39: mean of the area of the ellipse described by CoP in tandem condition. 
* 
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The mean of the values of the area of the ellipse described by CoP in Romberg’s 
condition increased in the strength group from 271 ± 107 mm² to 307 ± 344 mm², 
whereas in the standard group it decreased from 706 ± 237 mm² to 576 ± 231 
mm². 
The mean of the values of the area of the ellipse described by CoP in Romberg’s 
condition with eyes closed significantly decreased in the strength group from 763 
± 505 mm² to 565 ± 271 mm², whereas in the standard group it increased from 
1311 ± 640 mm² to 1667 ± 601mm². 
The mean of the values of the area of the ellipse described by CoP in tandem con-
dition decreased in the strength group from 932 ± 694 mm² to 841 ± 704 mm², 
whereas in the standard group it increased from 720 ± 337 mm² to 983 ± 797mm². 
 
3.12. Data about physical function 
 
Graph 40: mean of unipedal stance test, * between groups interaction p<0,05. 
 
The mean of the duration of the unipedal stance test significantly increased in the 
strength group from 23 ± 20 seconds to 32 ± 14 seconds, whereas in the standard 
group it decreased from 11 ± 13 seconds to 9 ± 7 seconds. 
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Graph 41: mean of timed up and go test, * between groups interaction p<0,05. 
 
 
Graph 42: mean of alternate step test, * between groups interaction p<0,05. 
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Graph 43: mean of scores of SPPB, * between groups interaction p<0,05. 
 
 
Graph 44: mean of 4 meters walk, # p<0,05 for time factor. 
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Graph 45: mean of 5 times sit to stand test, * between groups interaction p<0,05. 
 
The mean of the duration of the timed up and go test significantly decreased in the 
strength group from 8,9 ± 1,4 seconds to 8 ± 1,2 seconds, whereas in the standard 
group it increased from 9,7 ± 1,3 seconds to 10,1 ± 2 seconds. 
The mean of the duration of the alternate step test significantly decreased in the 
strength group from 10,5 ± 2,6 seconds to 8,4 ± 1,1 seconds, whereas in the stand-
ard group it decreased from 12,6 ± 2,4 seconds to 12,2 ± 2,6 seconds. 
The mean of total scores of the SPPB scale significantly increased in the strength 
group from 10,2 ± 1,7 to 11,3 ± 1, whereas in the standard group it decreased 
from 9,5 ± 1,4 to 8,8 ± 2,1. 
The mean of the duration of 4 meters walk significantly increased in time, from 
4,2 ± 0,7 seconds to 3,5 ± 0,6 seconds in the strength group, and from 4,2 ± 0,5 
seconds to 4 ± 0,7 seconds in the standard group. 
The mean of the duration of the sit to stand test significantly decreased in the 
strength group from 13 ± 3 seconds to 11 ± 2 seconds, whereas in the standard 
group it increased from 14 ± 2 seconds to 15 ± 3 seconds. 
 
* 
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3.13. Data about SF-36 questionnaire  
 
Graph 46: mean of the score of physical role limitations of SF-36 questionnaire. 
 
 
Graph 47: mean of score of physical activity of SF-36 questionnaire. 
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The mean of the score of physical role limitation of the SF-36 questionnaire in-
creased in the strength group from 68 to 75, whereas in the standard group it in-
creased from 63 to 73. 
The mean of the score of physical activity of the SF-36 questionnaire increased in 
the strength group from 69 to 78, whereas in the standard group it increased from 
56 to 66. 
 
3.14. Data about gait cycle 
 
Graph 48: mean of the coefficient of variation of stride time, # comparison between the ini-
tial and the final part of the entry test p<0,05 for time factor, + comparison between the final 
part of the entry del test and the final part of the exit test p<0,05 for time factor. 
 
The mean of the coefficient of variation of the stride time by the entry test signifi-
cantly increased in time between the initial and the final part of the test, from 1,6 
± 0,7 % to 1,9 ± 0,8 % in the strength group, and from 1,9 ± 0,3 % to 2 ± 0,5 % in 
the standard group, whereas by the exit test it decreased from 1,4 ± 0,4 % to 1,2 ± 
0,3 % in the strength group and from 1,9 ± 0,7 % to 1,8 ± 0,5 % in the standard 
group. 
# 
# 
+ 
+ 
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There were no significant differences between  the initial and the final part of the 
exit test, the final part of the test significantly decreased in time between pre and 
post training. 
 
 
Graph 49: mean of the coefficient of variation of the percentage of stance time on total, # 
comparison between the initial and the final part of the entry test p<0,05 for time factor, + 
comparison between the final part of the entry del test and the final part of the exit test 
p<0,05 for time factor. 
 
The mean of the coefficient of variation of the percentage of stance time on total 
by the entry test significantly increased in time between the initial and the final 
part of the test, from 1,6 ± 0,4 % to 1,8 ± 0,5 % in the strength group, and from 
1,8 ± 0,5 % to 2,4 ± 1,3 % in the standard group, whereas by the exit test it de-
creased from 1,6 ± 1,2 % to 1,4 ± 0,5 % in the strength group and remained un-
changed from 1,8 ± 0,7 % to 1,8 ± 0,7 % in the standard group.  
There were no significant differences between  the initial and the final part of the 
exit test, the final part of the test significantly decreased in time between pre and 
post training. 
+ 
+ # 
# 
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Graph 50: mean of the coefficient of variation of the percentage of swing time on total, # 
comparison between the initial and the final part of the entry test p<0,05 for time factor, + 
comparison between the final part of the entry del test and the final part of the exit test 
p<0,05 for time factor. 
 
The mean of the coefficient of variation of the percentage of swing time on total 
by the entry test significantly increased in time between the initial and the final 
part of the test, from 3,6 ± 1% to 4,4 ± 1,3% in the strength group and from 3,8 ± 
0,9 % to 4,5 ± 1,6 % in the standard group, whereas by the exit test it increased 
from 2,9 ± 1 % to 3,1 ± 0,9 % in the strength group, and from 3,5 ± 0,6 % to 3,8 ± 
1% in the standard group. 
There were no significant differences between  the initial and the final part of the 
exit test, the final part of the test significantly decreased in time between pre and 
post training. 
 
 
 
# 
# 
+ + 
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Graph 51: mean of the coefficient of variation of stance time, # comparison between the ini-
tial and the final part of the entry test p<0,05 for time factor, + comparison between the final 
part of the entry del test and the final part of the exit test p<0,05 for time factor. 
 
The mean of the coefficient of variation of the stance time by the entry test signif-
icantly increased in time between the initial and the final part of the test, from 2,1 
± 0,8 % to 2,4± 0,8 % in the strength group, and from 2,1 ± 0,6 % to 2,8 ± 0,9 % 
in the standard group, whereas by the exit test it decreased from 2,3 ± 1,8 % to 1,7 
± 0,5 % in the strength group and from 2,2 ± 0,8 to 2,1 ± 0,6 % in the standard 
group. 
There were no significant differences between  the initial and the final part of the 
exit test, the final part of the test significantly decreased in time between pre and 
post training. 
 
# # 
+ 
+ 
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Graph 52: mean of the coefficient of variation of swing time, # comparison between the ini-
tial and the final part of the entry test p<0,05 for time factor, + comparison between the final 
part of the entry test and the final part of the exit test p<0,05 for time factor. 
 
The mean of the coefficient of variation of the stance time by the entry test signif-
icantly increased in time between the initial and the final part of the test, from 4,2 
± 1,2 % to 5 ± 1,4 % in the strength group, and from 4,6 ± 1 % to 5,3 ± 1,4 % in 
the standard group, whereas by the exit test it increased from 3,5 ± 1 % to 3,7 ± 
1% in the strength group and from 4,3 ± 0,8 % to 4,5 ± 1% in the standard group. 
There were no significant differences between  the initial and the final part of the 
exit test, the final part of the test significantly decreased in time between pre and 
post training. 
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4. DISCUSSION 
 
Total walking distance, which is the primary end point of our study, significantly 
increased in both groups, as it could be expected on the basis of the literature
65
. 
Pain free walking distance that increased only in the strength group, seems to in-
dicate greater effectiveness of combined training respect to walking only. Indeed 
pain free walking distance highlights the walking ability in 'valid' perfusion condi-
tions, not in ischemia. This finding has therefore a special significance respect to 
total walking distance, being directly linked to the effective walking autonomy in 
everyday life, and thus highlighting the actual functional limitations of the patient. 
Data present in literature
81
 about the effects, on cardiovascular parameters of  
arteriopathic subjects, of a standard walking training respect of an experimental 
protocol of only strength exercises, show a decrease in systolic blood pressure at 
rest similar in both groups. Our data behave in a similar manner. 
The same study indeed didn’t find any difference for both groups in maximal 
pressure values. Our results also detected no difference in the standard group, 
while differences were found in the strength group. This leads us to think of an 
enhanced effect of combined training on cardiovascular parameters respect to  
walking only as well as resistance training alone. Indeed a lower systolic and dias-
tolic pressure in the strength group, both at pain free walking distance (diastolic) 
and at the end of the test, indicates a positive adjustment to the effort as a result of 
the training period, and shows greater levels of  fitness of the subjects and a po-
tential reduction of cardiovascular risk factors. 
The reduction in heart rate during exercise indicates a positive adaptation to the 
training. The previous study
81
 found differences in the heart rate at rest similar to 
those we detected. Instead there were no differences in maximal values, whereas 
our data show significant between groups differences, with a reduction of values 
in the strength group. This data further confirm the enhanced effect of combined 
training respect to each method alone. 
Variations in heart rate also resulted to by different between PAD patients and 
healthy adults in the early stages of an incremental walk test, and links were found 
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between these variations and those of values of oxygenated and deoxygenated 
hemoglobin
82
, with a reduction in submaximal heart rate linked to an increase in 
values of oxyhemoglobin or oxygen extraction ability. Such mechanisms might 
underlie the different between groups heart rate responses, measured in our study 
at the end of pain free walking distance.  
Previous studies
82,83
 used NIRS to evaluate values of oxygenated, deoxygenated 
and total hemoglobin in subjects with PAD. The values of the patients resulted 
significantly different respect to those of healthy controls, except total hemoglo-
bin. 
Also differences were found, after a period of unsupervised walking training, in 
values of oxyhemoglobin only in patients. The same study also found an increase 
in oxygen extraction ability at rest, especially in those subjects who didn’t in-
creased values of oxyhemoglobin. 
Our results show similar increase in the values of oxyhemoglobin by treadmill 
test, that probably indicates an increase of muscle vascularization. Our data also 
don’t show any significant increase in total hemoglobin, whose values don’t seem 
to be modified by the pathology. Only in the strength group there was an increase 
of the values of deoxyhemoglobin, which correspond to an increase in muscle ox-
ygen extraction ability, this should be linked to the increase in pain free walking 
distance. 
This effect, given the simultaneous increase in oxygen availability, seems to be a 
direct consequence of resistance training, and we assume a better muscle metabol-
ic and microcirculatory adaptation. 
One study
84
 reported a reduction of values of VO2 after an unsupervised walking 
training period, but at submaximal levels, indeed there doesn’t seem to be any dif-
ference at maximal levels. 
Also our results at total walking distance don’t show differences in the standard 
group, we found indeed a reduction of values of VO2 in the strength group. The 
reduction of oxygen consumption at the end of the test indicates an improvement 
in walking economy. This could be the result of the delayed onset of pain in this 
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group, which may in turn imply a gait closer to normality, with less energy ex-
penditure.  
The respiratory quotient at the end of training period increased in both groups, in 
concordance with literature. This indicates the ability of subjects to achieve a 
higher stress level. 
Data present in litterature
84
 don’t report differences between the values of flow 
volume at rest and post exercise. Our results are in agreement in the absence of 
differences in the standard group, whereas we found differences in the response 
following exercise in the strength group, possible consequence of increased vas-
cular reactivity, probably due to the improvement of endothelial function of vaso-
dilatation and recruitment of microcirculatory units. The data is particularly sig-
nificant with respect to the ability to generate hyperemia in the course of exercise, 
in order to meet the increased metabolic demands with strictly controlled vascular 
adaptations. 
Data present in litterature
84
 about lipid profile don’t report differences subsequent 
to standard training for total cholesterol and triglycerides, instead they found an 
increase in the values of HDL. Similarly, our data don’t report changes in the 
standard group in the values of total cholesterol and triglycerides, whereas both 
significantly decreased in the strength group. This indicates an improvement in li-
pid profile and cardiovascular risk reduction. Instead our results didn’t find any 
difference in either group for HDL cholesterol. 
One study
85 
found an increase in the levels of homocysteine, which indicates an 
inflammatory condition, following walking training and not following combined 
training. In our study, however, we found no significant differences in homocyste-
ine levels for either group.  
As a direct result of strength training we found an increase in maximal strength 
values in all muscle groups subjected to training. This is useful to contrast the loss 
of strength and muscle mass, due to aging and physical inactivity related to the 
disease, with positive effects on reducing the fall risk. 
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An high variability in the gait cycle parameter was linked to neuromotor control 
disorders, and is associated with an elevated fall risk
86,87,88
. Artheriopathic sub-
jects showed greater variability than healthy subjects, even walking without 
pain
89
. Few studies handled the effects of training on gait parameters
59
, and no 
differences were found.  
Our data show an increase in variability in the end of the entry test, with the onset 
of symptoms, this lets us assume a deterioration in the gait mechanics in the pres-
ence of pain. The same differences are not observed after training. We hypothesize 
that patients adapted to the exercise, by adopting a correct gait even in the pres-
ence of symptoms. This may lead to a better walking economy and could have a 
role in increasing total walking distance. The same differences are not found in the 
initial part of the test, which lets us exclude a simple learning effect. The differ-
ence between our results and the data of the literature, may be due to different 
methods used, or to the fact that our analysis was performed specifically on a 
range affected by claudication, and not on the total walk. 
Worst performances in the timed up and go test were associated with more severe 
stages of PAD
90
, and in the elderly higher executions times are associated with a 
higher fall risk
72
. In our study, the significant reduction of the execution time in 
the strength group indicates an improvement in dynamic balance and a decrease in 
the fall risk.  
 
The alternate step test is utilized in the general elderly population to identify sub-
jects whit high fall risk
73
, with more elevated execution times corresponding to 
worse performances. The data of the strength group show a significant reduction, 
going from higher to lower values than the threshold that discriminates subjects at 
high fall risk from general population. 
In subjects with PAD with an ABI severely decreased
91
 it was demonstrated a low 
speed in the 4 meters walking test. The increased performance observed in both 
groups subsequent to training confirms the improvements noted in walking auton-
omy. In contrast, the overall scores of SPPB scale, of which this test is part, in-
creased more in the strength group, showing an improvement in the static and dy-
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namic balance, as suggested by the reduction of execution times of 5 time sit to 
stand test. 
The area of the ellipse, described by CoP during the different positions of the bal-
ance test, shows a significant decrease in the strength group in the closed eye con-
dition and similar, but not significant, results in the tandem condition. There is no 
difference in any of the two groups in the Romberg’s open eye condition. The de-
crease in the area of the ellipse in the closed eye condition suggests an improve-
ment in static balance, which is usually decreased in PAD subjects
91
. The lack of 
differences in the initial conditions can be explained by the low difficulty of the 
test. 
Similar conclusions can be drawn from the results of the unipedal stance test, in 
which the data of the strength group passes from lower to higher value than the 
threshold that discriminates individuals at fall risk against the general population.  
From the results of tests that measure static and dynamic balance (timed up and 
go, alternate step, scale SPPB, unipedal stance, Romberg), improvements in the 
strength group emerge, which support the hypothesis of reducing fall risk. 
A study
92
 demonstrated that artheriopathic subjects every day make fewer steps 
and spend less time walking respect to healthy controls. Our data about daily ac-
tivity show an increase in the number of daily steps made in the strength group 
while there are no significant differences in the duration of physical activity, in-
cluding all periods of moderate or superior intensity activity, in any group. Previ-
ous studies
48
, similarly, found no difference in the duration of physical activity af-
ter a training period of 12 weeks. Instead increases were found after a 6 months 
period
47
. This results indicate the poor ability of artheriopathic subjects to tolerate 
long periods of activity also after training. The increase in the number of steps 
demonstrate how, reducing claudication, patients were stimulated to have a more 
active life style, which is known to affects life expectations of this subjects. 
The scores of SF-36 questionnaire about physical activity and physical role limita-
tions increased in both groups but differences aren’t significant. This is surprising 
because of the positive results obtained in the most part of the parameters.  
We hypothesize that the lack of results is not due to poor perception of improve-
ments by patients, but to the fact that the questionnaire is not specific for the pa-
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thology and scores of the majority of the subjects were already in line with the av-
erage of the population by age group. 
 
4.1. Limits of the study  
This study presents some limits. The main is the reduced number of patients in-
volved. Then there is the absence of deep analysis on bio humoral parameters and, 
lastly, the fact that it is a non-randomized study.   
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5. CONCLUSIONS 
In patients affected by PAD with intermittent claudication both combined and 
standard training demonstrated to be effective in increasing the principal autono-
my parameter : total distance walking. Combined training demonstrated to be 
more effective than the standard training to increase pain free walking distance. 
Moreover, combined training increased hyperemia of the limb during physical ac-
tivity, as well as improved important parameters of cardiorespiratory performance 
(oxygen consumption, heart rate, blood pressure, oxygen extraction). We also 
have documented the ability of combined training to increase muscle strength and 
balance, reducing the fall risk. We finally observed the transfer in the everyday 
life of positive effects, with a less sedentary life style. Therefore combined train-
ing could be utilized in patients with IC to improve not only performances but al-
so strength and equilibrium. 
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7. APPENDICES 
Parallel to the main study, we performed a detailed study of the effects of re-
sistance training on the skin microcirculation. 
Cutaneous circulation seems to be an interesting witness of hemodynamic modifi-
cation acting in lower limb also during muscles activation
112,113,114,115 
so we pro-
posed a test consisting  in a series of elevations on the forefoot repeated in a rapid 
sequence, standing with similar work amount compared to a sub-maximal exer-
cise on treadmill as used in training protocol.  
The aim is to evaluate the effects on cutaneous microcirculation, of a single bout 
of moderate strength exercise in PAD patients compared with aerobic treadmill 
exercise and controlled with healthy subjects.  
We enrolled 14  patients, with PAD at Fontaine stage II (pain free walking dis-
tance 130 ± 45 m - ABI 0,75 ± 11), aged 73 ± 4 y, no diabetic/neuropathic pa-
tients were allowed; all subjects had a superficial artery occlusion in the sympto-
matic leg with concomitant 1 or 2 tibial vessels occlusion. They underwent a se-
ries of up-standing on forefoot (FUP), successively they performed treadmill ex-
ercise  (3,2 Km/h, 0% slope) to 70% of maximal walking distance; the two exer-
cise were comparable for energy consumption calculated (on treadmill= 0,50 x km 
x kg of body weight, on heel elevation =  kg of body weight x m heel elevation x 
n° of elevation - respectively 61 ± 22 kcal and 55 ± 11 kcal, p=0,73);  10 healthy 
matched subjects performed FUP treadmill based on the same energy expenditure. 
We analyzed microcirculatory flux by means of Laser Doppler flowmetry with 
probe placed on forefoot of symptomatic leg in patients and on left leg in healthy 
volunteer; measurements were done at rest and after 1 minute after tests end and 
with a 2 minutes monitoring. Data were analyzed with Student’s t test for paired 
data. 
FUP caused a significant increase in microcirculatory flux in the recovery period 
in PAD patients (*p<0,05 vs rest – Graph1) while it caused no significant changes 
in healthy; treadmill caused a slight decrease in flux at PAD patient’s forefoot, 
while it caused an increase in healthy (*p<0,05 vs rest- Graph1).  
Our study has demonstrated that strength exercise in PAD patients with claudica-
tion causes an increase of cutaneous flux , while no significant changes in healthy. 
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Treadmill causes a decrease (not significant) in the period of monitoring as re-
ported in literature in PAD subjects. In healthy volunteers an increased flux after 
treadmill may be caused by hyperemia in the leg, elicited by exercise with a pre-
served inflow and a correct distribution in tissues
115,116
;  a component of ther-
moregulatory vasodilation may be evoked.  FUP in controls did not produce a rel-
evant phenomenon perhaps for sympathetic tone prevalence and a reduced overall 
hyperemia. In PAD patients the increase after FUP may be due to a more pro-
nounced ischemia and a more enhanced and concentrated vasodilation in a distal 
segment with sympathetic blunting and a more pronounced post exercise hypere-
mia due to a compensatory vasodilation, involving also cutaneous district.  This 
data may enforce the proposal for dedicated moderate-strength exercises for distal 
muscles groups in PAD patients.  
 
 
Graph 1: microcirculatory flux, * p<0,05 vs rest. 
 
 
